Pharmaceutical
Technology
Health

Agios

$48.61
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.49 (-2.97%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Agios and other stocks, options, ETFs, and crypto commission-free!

About

Agios Pharmaceuticals, Inc. Common Stock, also called Agios, is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. Read More It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Employees
482
Headquarters
Cambridge, Massachusetts
Founded
2007
Market Cap
2.94B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
471.32K
High Today
$49.90
Low Today
$47.43
Open Price
$49.51
Volume
261.82K
52 Week High
$99.82
52 Week Low
$41.63

Collections

Pharmaceutical
Technology
Health
Biotechnology
Biopharmaceutical
Cancer Prevention
2013 IPO
US

News

CNBCMay 15

Stocks making the biggest moves after hours: Agios, Farfetch, Cisco and more

Luxury fashion items sit on display beside tablet devices at the launch of the Farfetch "Store of the Future" pop-up exhibition, at the Design Museum in London, U.K., on Wednesday, April 12, 2017. Check out the companies making headlines after the bell: Shares of Cisco Systems rose more than 2.5% in extended trading Wednesday after the networking hardware company reported better-than-expected fourth quarter results. Cisco reported earnings of 78 cents per share, 1 cent above Wall Street's estimates, and r...

494
Seeking AlphaMay 15

Agios' ivosidenib successful in late-stage cholangiocarcinoma study

A Phase 3 clinical trial, ClarIDHy, evaluating Agios Pharmaceuticals' (NASDAQ:AGIO) TIBSOVO (ivosidenib) in previously treated patients with IDH1 mutation-positive cholangiocarcinoma met the primary endpoint of progression-free survival (PFS) compared to placebo.

61
Yahoo FinanceMay 9

Edited Transcript of AGIO earnings conference call or presentation 2-May-19 12:00pm GMT

Q1 2019 Agios Pharmaceuticals Inc Earnings Call Cambridge May 9, 2019 (Thomson StreetEvents) -- Edited Transcript of Agios Pharmaceuticals Inc earnings conference call or presentation Thursday, May 2, 2019 at 12:00:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Andrew Hirsch Agios Pharmaceuticals, Inc. - CFO & Head of Corporate...

10

Earnings

-$1.81
-$1.60
-$1.40
-$1.19
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.